PJ, October 2015, Vol 295, No 7882

Diabetes drug empagliflozin cuts cardiovascular deaths by nearly 40%

The diabetes drug empagliflozin could cut the number of cardiovascular deaths by almost 40% as part of the treatment for type 2 diabetes, according to a study published in New England Journal of Medicine.…

‘Digital pill’ assessed for approval by FDA

A drug embedded with a digital sensor that records when a patient’s stomach is ingesting the medicine is being assessed for approval by the US medicines safety watchdog.…

Taking blood pressure medication at bedtime reduces risk of developing diabetes

Taking blood pressure therapy first thing in the morning puts patients at a greater risk of developing diabetes than if they take their drugs as they settle down to sleep, researchers in Spain have shown.…

FDA gives the green light for cariprazine to treat schizophrenia or bipolar disorder

The US Food and Drug Administration has approved the atypical antipsychotic cariprazine (Vraylar) to treat adults with schizophrenia or bipolar disorder.…

Pharmacists should continue to follow Lyrica guidance, says PSNC

Pharmacists should continue to refer generic prescriptions for pregabalin back to the prescriber if they know it has been written for neuropathic pain, says the Pharmaceutical Services Negotiating Committee. …

Pharmacist trainees and tutors perceive quality of training differently

Preregistration pharmacists and their tutors have very different opinions about the quality of the training they receive, according to the results of two surveys.…